Search & Analyze

Alivus Life Sciences Ltd.

HealthcarePharmaceuticals & Drugs

www.alivus.com BSE: 543322NSE: ALIVUS

₹1,363.10BSE1.68%

16 Sep, 4:01 PM

₹1,363.10

₹16.84K Cr

27.92

4.83

18.41%

₹1,390.05

₹1,317.00

₹1,495.30

₹830.00

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	148.56	4,44,716.74	0.86	1,115.14	49.67%	5,741.13	2.61%	13.27
DIVI'S LAB. DIVISLAB	9,199.70	83.04	2,44,223.13	0.33	891.00	59.96%	2,974.00	26.18%	21.89
TORRENT PHAR TORNTPHARM	4,823.05	86.01	1,83,453.32	0.79	492.00	-10.71%	4,158.00	58.94%	19.77
ZYDUSLIFE ZYDUSLIFE	1,105.00	31.36	1,10,224.17	0.09	339.60	-11.72%	2,872.20	10.97%	16.05
CIPLA LTD. CIPLA	1,359.75	35.73	1,09,848.55	0.96	862.16	-33.84%	5,077.68	0.62%	14.04
LAURUSLABS LAURUSLABS	1,906.00	118.03	1,02,983.51	0.10	289.96	83.59%	1,757.16	22.64%	16.08
DR.REDDY'S DRREDDY	1,145.25	144.14	95,591.76	0.70	404.70	-86.33%	5,136.60	-34.23%	12.67
Alivus Life Sciences Ltd. ALIVUS	1,363.10	27.92	16,837.49	0.36	160.08	31.71%	640.41	6.41%	24.61

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	536.60	588.62	506.88	641.84	649.55	601.85	587.98	672.89	689.12	640.41
Expenses	395.15	429.13	372.52	451.54	451.11	429.53	408.81	441.62	474.59	428.70
	141.45	159.48	134.36	190.31	198.43	172.31	179.17	231.27	214.53	211.71
	26.36%	27.09%	26.51%	29.65%	30.55%	28.63%	30.47%	34.37%	31.13%	33.06%
	3.13	5.49	8.53	10.46	10.09	8.99	14.72	-11.73	22.78	22.40
Interest	0.36	0.35	0.34	0.46	1.26	1.25	1.32	1.49	1.31	1.31
	14.53	14.39	15.09	15.16	15.97	17.06	18.44	19.66	20.20	20.59
	129.68	150.24	127.46	185.15	191.29	162.98	174.14	198.39	215.80	212.22
	24.48%	25.80%	25.22%	26.03%	25.84%	25.43%	25.33%	24.26%	24.62%	24.57%
	97.94	111.48	95.32	136.96	141.87	121.54	130.03	150.26	162.66	160.08
	7.99	9.10	7.78	11.18	11.58	9.91	10.60	12.25	13.25	13.04

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	2,125.72	2,172.70	2,289.87	2,396.75	2,578.54
	2,123.21	2,161.22	2,283.21	2,386.88	2,551.83
EXPENDITURE :
Increase/Decrease in Stock	41.32	-84.44	-56.57	27.35	3.56
Raw Material Consumed	977.96	1,068.56	1,025.21	1,010.09	1,024.27
Power & Fuel Cost	100.92	115.60	112.46	117.24	113.88
Employee Cost	168.72	180.18	258.16	251.70	272.47
Other Manufacturing Expenses	124.04	137.17	163.64	177.41	212.31
General and Administration Expenses	54.18	46.46	55.14	52.57	58.17
Selling and Distribution Expenses	31.78	45.10	38.52	53.92	56.38
Miscellaneous Expenses	8.23	10.30	12.42	14.03	13.51
	1,507.15	1,518.93	1,608.97	1,704.30	1,754.55
Operating Profit (Excl OI)	616.06	642.29	674.25	682.58	797.28
	14.70	28.96	12.04	34.57	60.41
	630.76	671.25	686.29	717.15	857.70
Interest	27.96	0.55	1.55	2.41	5.37
PBDT	602.80	670.70	684.74	714.74	852.32
	37.88	42.09	53.45	60.61	75.36
Profit Before Taxation & Exceptional Items	564.93	628.61	631.29	654.13	776.97
Exceptional Income / Expenses					-25.66
	564.93	628.61	631.29	654.13	751.31
Provision for Tax	146.20	161.65	160.40	168.50	186.83
	418.72	466.96	470.89	485.63	564.48
Extra items				0.00	0.00
Consolidated Net Profit	418.72	466.96	470.89	485.63	564.48
Profit Balance B/F	750.79	1,021.35	1,102.06	1,291.80	1,777.18
Appropriations	1,169.51	1,488.31	1,572.95	1,777.43	2,341.66
Equity Dividend %	1,050.00%	1,050.00%	1,125.00%	250.00%	250.00%
	34.17	38.11	38.43	39.63	45.99
Adjusted EPS	34.17	38.11	38.43	39.63	45.99

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	24.51	24.51	24.51	24.51	24.55
Share Warrants & Outstandings	3.50	6.68	11.06	9.97	7.25
Total Reserves	2,026.31	2,107.02	2,296.76	2,782.90	3,300.34
Reserve excluding Revaluation Reserve	2,026.31	2,107.02	2,296.76	2,782.90	3,300.34
	2,054.31	2,138.21	2,332.32	2,817.37	3,332.13
Deferred Tax Assets / Liabilities	31.50	42.43	48.79	54.43	57.79
Other Long Term Liabilities	1.20	17.09	14.76	50.96	48.79
Long Term Provisions		7.87	693.41	360.67	36.15
Total Non-Current Liabilities	32.70	67.40	756.95	466.05	142.73
Trade Payables	307.72	427.23	368.66	390.46	372.37
Other Current Liabilities	49.84	54.57	58.08	62.74	99.30
Short Term Provisions	389.24	533.09	12.03	16.96	210.57
Total Current Liabilities	746.80	1,014.89	438.77	470.16	682.24
Total Liabilities	2,833.81	3,220.49	3,528.05	3,753.59	4,157.10
Gross Block	705.53	936.48	1,012.33	1,218.71	1,366.62
Less: Accumulated Depreciation	115.77	155.85	207.26	263.76	329.07
Net Block	589.76	780.63	805.06	954.95	1,037.55
Capital Work in Progress	91.69	49.35	101.19	94.25	273.40
Non Current Investments	0.08	0.08	0.08	0.08	0.08
Long Term Investment	0.08	0.08	0.08	0.08	0.08
Long Term Loans & Advances	19.63	9.49	700.92	361.49	12.16
Total Non-Current Assets	706.42	851.81	1,612.05	1,418.43	1,333.54
Currents Investments				477.62	780.38
Inventories	516.24	604.17	666.59	673.95	691.93
Sundry Debtors	673.49	806.77	765.43	969.74	1,072.96
Cash and Bank	512.16	309.40	301.59	71.24	2.13
Other Current Assets	5.96	71.72	91.69	42.25	38.70
Short Term Loans and Advances	419.54	576.63	90.69	100.37	237.46
Total Current Assets	2,127.39	2,368.68	1,916.00	2,335.16	2,823.56
Net Current Assets (Including Current Investments)	1,380.59	1,353.80	1,477.23	1,865.00	2,141.33
Total Assets	2,833.81	3,220.49	3,528.05	3,753.59	4,157.10
Contingent Liabilities	2.22	2.22	4.82	4.82	4.82
Total Debt	0.00	0.00	0.00	0.00	0.00
	167.38	173.97	189.45	229.11	270.90
Adjusted Book Value	167.38	173.97	189.45	229.11	270.90

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	564.93	628.61	631.29	654.13	751.31
Adjustment	70.99	44.62	79.27	80.72	115.90
Changes In working Capital	99.84	-213.66	-134.08	-180.38	-128.54
Cash Flow after changes in Working Capital	735.75	459.57	576.48	554.48	738.67
Cash Flow from Operating Activities	597.59	306.01	413.52	391.52	565.41
Cash Flow from Investing Activities	-122.23	-146.75	-116.48	-615.65	-570.15
Cash Flow from Financing Activitie	-78.80	-387.59	-279.44	-6.23	-64.34
Net Cash Inflow / Outflow	396.56	-228.33	17.59	-230.35	-69.08
Opening Cash & Cash Equivalents	115.60	512.16	283.82	301.41	71.06
Closing Cash & Cash Equivalent	512.16	283.82	301.41	71.06	1.98

Ratios

Valuation

27.92

4.83

18.49

6.50

49.12

283.86

Profitability

18.41

24.61

14.27

30.92

21.89

Leverage & Liquidity

0.00

4.14

140.86

Returns

0.36

0.65

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	82.85	75.00	75.00	74.99	74.94	74.91	74.91	74.87	74.87
	6.39	12.01	11.60	11.76	12.03	12.31	12.21	12.57	12.72
	10.76	12.99	13.40	13.25	13.03	12.78	12.88	12.56	12.41
	17.15	25.00	25.00	25.01	25.06	25.09	25.09	25.13	25.13
No. of Shareholders	1,49,396	1,43,960	1,46,840	1,41,977	1,38,500	1,35,643	1,32,748	1,27,969	1,25,559

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-08-06	AGM
2026-07-23	Board Meeting	Quarterly Results
2026-05-14	Ex Dividend	Rs.5.0000 per share(250%)Final Dividend	2026-09-01	2026-09-01

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Alivus Life Sciences Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

8 members across the board and senior leadership

Rudalf Corriea

Company Secretary & Compliance Officer

—

Hiren K Patel

Chairman

—

Yasir Rawjee

Managing Director & Chief Executive Officer

₹16.38 Cr

Mar '26

Kaushikbhai N Patel

Non Executive Independent Director

₹15.00 L

Mar '26

Manju Agarwal

Non Executive Independent Director

₹13.00 L

Mar '26

TL Easwar

Non Executive Independent Director

₹11.00 L

Mar '26

Savan Godiawala

Non Executive Independent Director

₹14.00 L

Mar '26

Vinod Naik

Whole Time Director - Technical Operations

₹3.69 Cr

Mar '26

ALIVUS Latest News

News

3 of 3 articles

COMPANY19 Aug 2026 · 14:09

Alivus Life Sciences gets nod to acquire 76% stake in IQGEN-X Pharma

The Board of Directors of the company at its meeting held on August 18, 2026, approved the same

EQUITY13 Aug 2026 · 14:59

Alivus Life Sciences informs about newspaper publication

EQUITY14 May 2026 · 19:34

Alivus Life Sciences reports Profit after tax of Rs 1626.61 Mln, in the March 2026 quarter

ALIVUS

₹1,363.10

+1.68%